Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of nausea and vomiting-inducing conditions
3.2.1.2 Growing availability of reimbursement and coverage for antiemetic drugs
3.2.1.3 Advancements in drug formulations
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects and safety concerns
3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Gap analysis
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Serotonin-receptor antagonists
5.3 Anticholinergics
5.4 Glucocorticoids
5.5 Dopamine receptor antagonists
5.6 Neurokinin receptor antagonists
5.7 Antihistamines
5.8 Other drug types
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Chemotherapy induced nausea and vomiting (CINV)
6.3 Gastroenteritis
6.4 Postoperative nausea and vomiting (PONV)
6.5 Other applications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Astellas Pharma Inc.
10.2 Baxter International Inc.
10.3 Cipla Limited
10.4 Eagle Pharmaceuticals, Inc.
10.5 Glenmark Pharmaceuticals Limited
10.6 GSK plc
10.7 Hikma Pharmaceuticals PLC
10.8 Johnson & Johnson
10.9 Merck & Co., Inc.
10.10 Novartis AG
10.11 Pfizer Inc.
10.12 Takeda Pharmaceutical Company Limited
10.13 Teva Pharmaceutical Industries Limited
10.14 Torrent Pharmaceuticals Limited
10.15 Viatris Inc.
